SKIN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Beauty Health Co (SKIN) is not a strong buy at the moment for a beginner investor with a long-term horizon. The stock shows bearish technical indicators, weak financial performance, and no significant positive catalysts to justify an immediate investment. While hedge funds are buying, the lack of strong growth signals and negative analyst sentiment suggest a cautious approach.
The stock is exhibiting bearish technical indicators. The MACD histogram is negative and expanding downward, RSI is neutral at 20.329, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.952 and 0.846, with resistance at 1.125 and 1.297.
Hedge funds are significantly increasing their buying activity, with an 87233.33% increase in the last quarter. Gross margin improved to 73.13%, up 5.92% YoY.
Revenue dropped by -1.35% YoY in Q4 2025, net income fell by -21.55% YoY, and EPS declined by -25.00% YoY. Analysts recently lowered the price target from $1.65 to $1.50, citing macro pressure and softer Q1 expectations. No recent news or congress trading data to support a positive sentiment.
In Q4 2025, revenue dropped to $82.37M (-1.35% YoY), net income fell to -$8.10M (-21.55% YoY), and EPS decreased to -0.06 (-25.00% YoY). Gross margin increased to 73.13% (+5.92% YoY), indicating some operational efficiency.
Analysts have a Hold rating on the stock. The price target was recently lowered from $1.65 to $1.50 due to macroeconomic pressures and weaker Q1 expectations. However, FY26 EBITDA guidance suggests a potential 20% upside, though this is contingent on improved distributor activity.
